Kanaph Therapeutics Q1 2026: Cash holdings of 48.9bn won, KOSDAQ listing and technology transfer expansion
As of Q1 2026, held total cash and equivalents of 48.9bn won (11.9bn won cash + 37bn won short-term financial products), a significant increase from 13.5bn won at year-end 2025.
Debt ratio of 4.41%, maintaining very low leverage (24.90% at year-end 2025).
Revenue of 78mn won from research services, sharply down from 5.25bn won in full year 2025 (technology transfer revenue).
Operating loss of 5.4bn won and net loss of 5.3bn won (including R&D expenses of 1.65bn won).